Premium
Enhancement by stable butyrate derivatives of antitumor and antiviral actions of interferon
Author(s) -
Pouillart Philippe,
Cerutti Italina,
Ronco Gino,
Villa Pierre,
Chany Charles
Publication year - 1992
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910510416
Subject(s) - butyrate , prodrug , in vivo , interferon , butyric acid , in vitro , pharmacology , virus , cell culture , alpha interferon , nucleoside analogue , chemotherapy , biology , cancer research , virology , nucleoside , biochemistry , genetics , microbiology and biotechnology , fermentation
The use of n‐butyric acid has been associated with induction of cell differentiation and bypassing of genetic defects in the suppression of malignancy. This biological response modifier satisfies the requirements for specificity and low toxicity, and its use can be considered as an alternative approach to conventional cancer chemotherapy. However, a lack of clinical efficacy has been observed with butyrate and attributed mainly to the rapid metabolism of the compound. Butyric acid pro‐drugs derived from monosaccharides such as 3‐O‐butanoyl‐1,2‐O‐isopropylidene‐α‐D‐glucofuranose (MAG=3but) have consequently been devised. Pharmacokinetic and biological advantages of MAG=3but have been previously described. In the present report, we have studied the effect of MAG=3but on murine interferon‐α,β (IFN) anticellular, antitumor and antiviral activities, In vitro , it appears that MAG=3but predisposes malignant MSV cells to a later, complete establishment of the antiproliferative and the cell‐differentiating effects of IFN, and the antiviral action of the latter in the same line of cells infected with encephalomyocarditis (EMC) virus. In vivo , combined treatment with MAG=3but and IFN protects mice effectively against the fatal development of ascitic sarcoma 180 TG and the lethal effect of EMC virus infection.